What happens to bones after menopause and how to protect them

After menopause, bone loss accelerates because declining estrogen levels shift normal bone remodeling toward destruction: old bone is removed faster than new bone can be formed. As a result, mineral density gradually decreases, bone structure deteriorates, and the risk of low-energy fractures—primarily of the vertebrae, hip, and forearm—increases. [1]

The period around the last menstrual period is particularly important. The SWAN longitudinal study found that the acceleration of bone mineral loss at the lumbar spine and femoral neck begins approximately one year before the last menstrual period, is most pronounced until approximately two years after, and then slows but does not cease. Over the ten years studied around menopause, the average bone mineral loss was approximately 10.6% at the spine and 9.1% at the femoral neck, with most of this loss occurring during the transition period. These figures are representative of the population studied and do not predict the individual rate of bone loss in any given woman. [2]

The problem is that bone loss is usually undetectable. Osteoporosis can cause no pain for years and is often first detected after a fracture due to a fall from standing height or after a vertebral compression fracture is diagnosed. Therefore, after menopause, it is more important to assess risk factors and undergo dual-energy X-ray absorptiometry (DXA) scans promptly rather than wait for symptoms to develop. [3]

What exactly changes inside the bone?

Bone is not a fixed mineral structure. Throughout life, it undergoes constant remodeling: osteoclasts remove areas of old or damaged tissue, after which osteoblasts form new bone in their place. As long as these processes are balanced, the skeletal structure is maintained.

Following a decline in ovarian function, this balance shifts. Estrogens are involved in the regulation of bone metabolism, and prolonged estrogen deficiency after menopause is accompanied by increased bone resorption. If the volume of destroyed tissue systematically exceeds the volume of newly formed tissue, a gradual loss of bone mass and strength occurs. [4]

That's why the term "calcium loss after menopause" oversimplifies the process. The problem isn't just the amount of calcium in the diet. The rate of bone turnover itself changes, and with it, the mineral density and spatial organization of the bone.

This distinction has practical implications. If a woman already has a high fracture risk or osteoporosis, increasing dairy consumption or calcium intake alone will not restore impaired bone remodeling to normal and is not a substitute for specific treatment. [5]

When bone is lost the fastest

The most intense changes begin even before a woman officially becomes postmenopausal.

In SWAN, bone mineral density loss in the spine and femoral neck began approximately one year before the last menstrual period. The rate of loss peaked from one year before to approximately two years after. The rate then slowed, but bone loss continued. [6]

The American College of Obstetricians and Gynecologists describes this process somewhat more broadly, stating that more rapid bone loss is typical for the first 4-8 years after menopause. These formulations are not necessarily contradictory: SWAN allowed for a more precise correlation of the peak rate with the last menstrual period, while clinical literature describes a longer period of increased bone vulnerability. [7]

Another SWAN analysis examined not only bone mineral density but also the trabecular bone score, an indirect measure of the microarchitecture of the spinal cancellous tissue. Its decline also began approximately one and a half years before the last menstrual period and continued afterward. This demonstrates why discussions of bone health cannot be reduced solely to the amount of mineral in a single DXA measurement. [8]

What happens to the internal architecture of the bone?

Bone strength is determined by more than just its mineral density. The arrangement of bone trabeculae, the thickness of the cortical layer, bone geometry, and accumulated microdamage are also important.

SWAN studies of the hip region showed that not only mineral density but also geometric parameters of the proximal femur changed around the menopausal transition. The most rapid changes again occurred around the last menstrual period. [9]

This helps explain the apparent paradox: two women with similar bone mineral density values may have different fracture risks. DXA remains the primary clinical method for assessing bone mineral density, but it does not measure all components of skeletal strength.

Trabecular bone index can further refine risk assessment in some situations. The International Society of Clinical Densitometry considers it associated with the risk of vertebral, hip, and major osteoporotic fractures in postmenopausal women and allows its use in conjunction with FRAX and bone mineral density. However, TBS should not alone guide treatment decisions. [10]

Osteopenia and osteoporosis are not the same thing.

Osteopenia means a decrease in mineral density that has not yet reached the densitometric threshold for osteoporosis.

For postmenopausal women, DXA typically uses the T-score, which compares a person's BMD to a reference value for young adults.

T-test	Densitometric interpretation
-1.0 and above	Normal mineral density
Below -1.0, but above -2.5	Low bone mineral density, often called osteopenia
-2.5 and below	Meets the densitometric criterion for osteoporosis

The International Society of Clinical Densitometry accepts the diagnosis of osteoporosis in postmenopausal women with a T-score of -2.5 or lower at the lumbar spine, total hip, or femoral neck.[11]

However, the T-score is not a complete predictor of future fractures. The International Menopause Society, in its 2025 guidelines, specifically emphasizes that low BMD is only one risk factor, and decisions about preventive treatment should take into account the entire clinical profile. [12]

Why a fracture is possible even with osteopenia

This is one of the most important nuances that is often lost in popular materials about menopause.

The -2.5 threshold was created for standardized classification of bone mineral density. It is not a biological limit above which bone is "safe" and below which it suddenly becomes brittle.

Age, previous fractures, risk of falls, family history of hip fracture, glucocorticoid use, certain medical conditions, and other factors alter the likelihood of fracture independent of the T-score. Therefore, modern medicine assesses fracture risk, not just the DXA result. [13]

The trabecular bone index also shows that bone structural characteristics are able to add prognostic information independent of conventional mineral density.[14]

Therefore the phrase:

"I only have osteopenia, so I'm not at risk of a fracture."

Incorrect.

One woman with osteopenia will have a truly low overall risk and won't need medication. For another, a combination of age, a previous fracture, and other factors will make the risk high enough to warrant consideration of drug therapy.

Why osteoporosis doesn't hurt

A gradual loss of bone density is usually not felt. There is no mechanism inherent in the loss of mineral mass that would necessarily cause chronic bone pain.

The International Osteoporosis Foundation and the National Institute of Arthritis and Musculoskeletal and Skin Diseases call osteoporosis a "silent" disease: symptoms often appear only after a fracture. [15]

Vertebral fractures are especially easy to miss. They are not always accompanied by a significant injury and sometimes occur with normal weight-bearing activities. The consequences can include decreased height or the development of kyphosis—a pronounced rounding of the upper back. Some vertebral fractures heal without severe, acute pain. [16]

Therefore, the absence of pain after menopause does not say anything about bone mineral density.

What fractures are particularly associated with osteoporosis?

Classic osteoporotic sites include the spine, proximal femur, and forearm. The FRAX calculator classifies the primary osteoporotic fractures as clinical fractures of the spine, femur, forearm, and humerus. [17]

The most clinically significant is a hip fracture, as it can dramatically reduce the mobility and independence of an elderly person.

Vertebral fractures are important for another reason: some remain unrecognized. Therefore, the NOGG recommends considering spinal imaging in patients with acute back pain associated with osteoporotic risk factors, height loss of at least 4 cm, kyphosis, long-term glucocorticoid therapy, or a T-score of −2.5 or lower. [18]

Who loses bones especially quickly after menopause?

Menopause increases the likelihood of bone loss, but individual risk varies widely.

Among the clinically significant factors, the NOGG and USPSTF name low body weight, previous fragility fracture, parental hip fracture, smoking, significant alcohol consumption, long-term use of systemic glucocorticoids, and certain chronic diseases. [19]

NOGG additionally takes into account rheumatoid arthritis, diabetes, malabsorption, bariatric surgery, chronic diseases of the liver, kidneys, lungs and nervous system, hyperthyroidism, hyperparathyroidism, premature menopause and treatment with aromatase inhibitors. [20]

Having a risk factor doesn't necessarily mean a woman will develop osteoporosis. However, it does lower the threshold for assessing fracture risk and performing DXA.

Early menopause is especially important for bones.

The earlier normal ovarian function ceases, the longer the skeleton remains in conditions of reduced estrogenic stimulation.

The European Society of Endocrinology defines early menopause as occurring between 40 and under 45 years of age, and premature ovarian failure as the cessation of ovarian function before age 40. The guidelines specifically include assessment of bone health in premature ovarian failure. [21]

For this group, the strategy differs from the usual natural menopause around age 50. The European Society of Endocrinology recommends hormone replacement therapy for premature ovarian failure, regardless of the presence of hot flashes and other symptoms, and typically continues it until the expected age of natural menopause, unless contraindicated. The goals of such therapy include reducing the long-term consequences of early estrogen deficiency, including bone damage. [22]

Therefore, a woman who has lost ovarian function at 35-40 years of age and a woman with natural menopause at a normal age are not the same clinical situations.

Should every woman have a bone density test immediately after menopause?

There is no uniform international rule for DXA testing for everyone immediately after their last menstrual period. Most systems use age plus risk assessment.

In its updated guidelines from January 2025, the USPSTF recommends screening all women aged 65 and older. Postmenopausal women under 65 are initially assessed for risk factors and use a clinical risk assessment tool; DXA is performed for those at increased risk. [23]

The International Menopause Society, in its 2025 guidelines, proposes a somewhat more proactive approach: assess perimenopausal and early postmenopausal women with FRAX without DXA or another local tool, and perform DXA if a risk is identified; all women should have DXA by age 65 if the test has not been performed earlier. [24]

The British National Orthopedic Group (NOGG) recommends not automatically performing DXA first for all postmenopausal women, but starting with FRAX if a clinical risk factor is present. At intermediate risk, DXA helps clarify the likelihood of fracture, and at high or very high risk, it is also used as a starting point for treatment and monitoring. [25]

The difference between the systems therefore exists primarily in the organization of screening, rather than in the understanding of the disease: in all cases, a woman aged 65 years and older, or a younger woman with significant risk factors, deserves a bone health assessment.

Who may need densitometry before age 65?

Early DXA is especially useful if there are factors that can significantly increase the risk of fracture.

For example:

• low-energy fracture;
• low body weight;
• early or premature menopause;
• parental hip fracture;
• smoking;
• significant alcohol consumption;
• long-term use of systemic glucocorticoids;
• rheumatoid arthritis;
• some endocrine diseases;
• treatment with aromatase inhibitors;
• other causes of secondary osteoporosis. [26]

Therefore, it is better to formulate the question not:

"I'm 55 - am I eligible for a densitometry test?"

A:

"What is my overall fracture risk and will the DXA result change my next steps?"

What does DXA show?

Dual-energy X-ray absorptiometry measures bone mineral density. The primary diagnostic areas are the lumbar spine and hip region. [27]

The test is quick, non-invasive and involves very little radiation exposure. [28]

Its main advantage is the standardized quantitative assessment of density and the ability to use the result in conjunction with other risk factors.

However, DXA is not a direct test of whether a bone will break. It measures one very important component of strength, but not all bone characteristics or the likelihood of a fall.

Therefore, a normal or moderately reduced T-score does not preclude consideration of the clinical context. [29]

What is FRAX and why is it needed?

FRAX is a tool for calculating the 10-year probability of hip fracture and major osteoporotic fractures based on age and a range of clinical risk factors; femoral neck mineral density can be added if data are available. [30]

Its basic idea is that the same T-score means different clinical risk in different people.

For example, a 52-year-old woman with a T-score of -2.0, no fractures, and no additional risk factors and a 78-year-old woman with the same score, a previous fracture, and a family history of hip fracture are in very different situations.

However, FRAX is not a perfect predictor. NOGG emphasizes the need for clinical judgment if circumstances exist that the tool does not adequately account for, such as falls, high doses of glucocorticoids, type 2 diabetes, or significant differences between spine and hip density. [31]

Can age-related bone loss be stopped?

It is impossible to completely stop the biological aging of the skeleton, but it is possible to significantly change the risk of osteoporosis and fractures.

The International Menopause Society recommends that all women after menopause adopt a bone-friendly lifestyle: regular physical activity with strength and resistance training, fall prevention, and a balanced diet with sufficient calcium and vitamin D. [32]

Longitudinal SWAN data also show that greater physical activity during transition was associated with a slower decline in femoral neck mineral density and higher subsequent bone mineral density at the spine and hip. These are observational data, so they do not prove that movement alone explains the difference, but they are consistent with the overall evidence base for physical activity. [33]

A 2025 meta-analysis of 17 randomized trials of resistance training in postmenopausal women found improvements in bone mineral density at the lumbar spine, femoral neck, and total hip. However, for the spine and femoral neck, the results were highly heterogeneous, so no single "ideal bone program" can be deduced. [34]

What kind of exercise is good for bones?

Bone adapts to mechanical stress. Therefore, activities that place the skeleton under load, either through body weight or muscle resistance, are particularly valuable.

In practice this means a combination of:

• walking and other tolerable body weight-bearing activity;
• resistance training;
• balance and coordination exercises, especially at an older age.

The International Menopause Society recommends that middle-aged and older women engage in regular exercise for muscle and bone health and at least two additional strength training sessions per week along with aerobic activity.[35]

If severe osteoporosis or spinal compression fractures already exist, the training program must take into account the risk of specific movements and falls. Here, the goal shifts from prevention to individualized rehabilitation and preventing further fractures.

Calcium: The More the Better?

No. Calcium is necessary for normal bone mineralization, but increasing the dose beyond the required amount does not make it a cure for osteoporosis.

In 2025, the International Menopause Society recommended that all postmenopausal women meet the recommended intake of calcium and vitamin D, primarily as part of a bone-healthy lifestyle. For women with postmenopausal osteoporosis, the society recommends approximately 1200 mg of calcium and 800 international units of vitamin D per day, but does not recommend routine calcium and vitamin D supplementation for all healthy women without osteoporosis or deficiency solely for fracture prevention. [36]

This is consistent with a more recent evidence base. A 2025 meta-analysis of 11 randomized trials in postmenopausal women with osteoporosis found only limited changes in bone mineral density with calcium plus vitamin D and no statistically significant reduction in overall clinical fracture rates in a pooled analysis. [37]

Therefore, it is more appropriate to first assess nutrition and the risk of deficiency, rather than automatically prescribing maximum supplement doses to every woman after her last menstrual period.

Vitamin D is important, but it is not a stand-alone treatment for osteoporosis.

Vitamin D is essential for normal calcium metabolism and bone health. Correcting deficiency is especially important.

However, vitamin D supplementation does not replace anti-osteoporotic therapy in women at high risk of fracture.

The Endocrine Society views calcium and vitamin D primarily as adjuncts to specific treatments for postmenopausal osteoporosis, and not as equivalent to bisphosphonates, denosumab, or anabolic steroids.[38]

This is one of the reasons not to confuse the two concepts:

Maintaining normal bone metabolism

AND

Treatment of a disease with a high risk of fracture.

Does menopausal hormone therapy help bones?

Yes. Systemic menopausal hormone therapy prevents bone loss and reduces the risk of fractures. However, its use depends on age, time since menopause, symptoms, and overall risk profile.

The new 2025 European Society of Endocrinology guidelines recommend informing women starting hormone therapy within ten years of natural menopause or before age 60 due to menopausal symptoms that the therapy prevents bone loss and reduces the risk of fractures. For some asymptomatic women under age 60, hormone therapy may also be considered for bone protection. [39]

The International Menopause Society goes a step further in its new guidelines, calling MHT a first-line therapy for the prevention of menopause-related bone loss, particularly when treatment is started within ten years of menopause or before age 60 and the benefit-to-risk ratio is favorable.[40]

The UK NOGG, after its 2024 update, also considers hormonal therapy to be a first-line option in younger postmenopausal women – up to 60 years of age – with a high risk of fracture and a low baseline risk of malignant and thromboembolic complications. [41]

This doesn't mean that every woman after menopause should start hormone therapy for the sake of her bones. The decision remains individual.

Hormone therapy and treatment of established osteoporosis are not the same thing.

This distinction is particularly important.

The European Society of Endocrinology notes that systemic hormonal therapy effectively prevents bone loss and reduces fracture risk, but is not considered a first-line treatment for established postmenopausal osteoporosis, especially when a woman has a high or very high fracture risk. More specialized bone medications are available for these patients. [42]

Therefore, a 52-year-old woman with hot flashes and incipient bone loss has one therapeutic logic, while a 75-year-old woman with multiple vertebral fractures has a completely different one.

This explains the apparent discrepancy between recommendations about the benefits of hormones for bones and recommendations to use bisphosphonates or anabolic drugs in established osteoporosis.

How is postmenopausal osteoporosis treated?

Treatment is selected not only based on the T-score, but also on the overall fracture probability and risk category.

The NOGG recommends drug therapy for people at high and very high risk and particularly emphasizes the need to start it soon after a fragility fracture, as the risk of recurrent fracture is highest in the immediate period. [43]

For many high-risk women, antiresorptive drugs—primarily bisphosphonates such as alendronate, risedronate, or intravenous zoledronate—are standard initial treatment options. The Endocrine Society also considers bisphosphonates to be the primary initial pharmacologic therapy for high-risk postmenopausal women. [44]

Denosumab is an effective alternative in certain situations. It has a fundamental difference from bisphosphonates: treatment cannot be simply discontinued arbitrarily or the next dose significantly delayed. After discontinuation, the suppression of bone turnover quickly disappears, mineral density can decrease sharply, and the risk of fractures increases; therefore, subsequent antiresorptive therapy must be planned in advance. [45]

For women at very high risk, such as those with multiple vertebral fractures, bone anabolic agents such as teriparatide, abaloparatide, or romosozumab may be used, followed by a switch to an antiresorptive agent to maintain the effect achieved. [46]

Why Osteoporosis Treatment Isn't Just a Course of Pills

Modern recommendations increasingly view osteoporosis as a chronic disease for which it is necessary to plan the treatment sequence in advance.

The International Menopause Society clearly emphasizes that osteoporosis is a lifelong condition, and the duration of treatment, switching between drugs, and possible periods without therapy depend on the specific drug and the level of risk. [47]

With bisphosphonates, after several years of treatment, a controlled break may be possible in some low- or moderate-risk women.

Denosumab does not have this principle: its discontinuation requires subsequent therapy.

After anabolic drugs, on the contrary, an antiresorptive stage is almost always required, otherwise the resulting increase in bone tissue is gradually lost. [48]

Therefore, changing or stopping osteoporosis medications on your own is especially undesirable.

Is it possible to restore lost bone?

Partially - yes, but the result depends on the initial condition and the method of treatment.

Antiresorptive drugs primarily reduce bone loss and can increase bone mineral density. Anabolic drugs directly stimulate the formation of new bone tissue and are used primarily in patients with a very high risk of fractures. [49]

But the goal of therapy is not necessarily to return the T-score to the numbers of a young woman.

The main clinical outcome is a reduction in the likelihood of future fracture.

This is why a drug that moderately changes DXA values may have high medical value if it is shown to reduce fracture rates.

Can bone density be restored through exercise alone?

Exercise is helpful, but in established high-risk osteoporosis it is usually part of treatment rather than a replacement for drug therapy.

Meta-analyses confirm that exercise training can moderately improve or maintain spine and hip mineral density in postmenopausal women.[50]

But the magnitude of such a change is usually much smaller than the difference between a woman with severe osteoporosis and normal bone density.

In people with a high risk of fracture, exercise is especially valuable because it strengthens muscles and helps reduce the risk of falls. The National Institute of Osteoporosis recommends assessing the risk of falls in people with osteoporosis and offering appropriate strength and balance exercises. [51]

Why Post-Menopause Height Loss Can't Just Be Attributed to Age

A few millimeters of height change over decades does not in itself prove the presence of a fracture. However, significant height loss can be a consequence of vertebral compression fractures.

NOGG uses a height loss of 4 cm or more as one indication to consider spinal imaging to look for an occult fracture in a person at risk of osteoporosis.[52]

Progressive kyphosis—the development of a pronounced stoop or rounding of the thoracic spine—may also accompany multiple vertebral fractures. [53]

Therefore, a noticeable decrease in height after menopause is not a reason to panic, but a good reason to discuss a bone examination.

When you shouldn't delay a medical evaluation

Osteoporosis is usually not an emergency, but some situations require prompt evaluation.

A fracture following a minor injury—for example, a fall from standing height—should prompt an assessment of the risk of bone fragility, especially after age 50. The NOGG recommends initiating secondary fracture prevention without undue delay, as the risk of another fracture is particularly high immediately after the first fracture. [54]

New onset of severe back pain in a woman with risk factors for osteoporosis may prompt evaluation for a vertebral compression fracture.[55]

After a fall with severe pain in the hip area and the inability to stand or put weight on the leg, an urgent trauma assessment for a possible hip fracture is required.

A significant decrease in height, the development of kyphosis, prolonged use of systemic glucocorticoids, or early menopause are reasons not to expect standard age-related screening.

A practical algorithm after menopause

If menopause occurs at a normal age and there are no significant risk factors, there is no need to immediately begin medications or endlessly measure bone density. A rational first step is to maintain strength- and weight-bearing physical activity, eat a balanced diet, avoid smoking, and limit excess alcohol consumption. [56]

It is then useful to assess personal risk factors: have there been fractures following minor trauma, a parent with a hip fracture, low body weight, long-term glucocorticoid use, rheumatological or endocrine diseases, or premature menopause. If these are present, it makes sense to conduct a formal fracture risk assessment and consider DXA. [57]

By age 65, international and American recommendations agree on the need for screening for mineral density in women if it has not been performed earlier for indications. [58]

If DXA reveals decreased density, the next question is not simply "osteopenia or osteoporosis," but what is the absolute fracture risk. This is determined by fracture history, age, FRAX, and other clinical factors. [59]

If the risk is high, the doctor will discuss specific therapy. If the risk is low, the focus typically remains on lifestyle changes and subsequent reassessment at an appropriate time.

What is often misunderstood

"Bones only start to deteriorate after formal menopause." Longitudinal studies show that accelerated loss of bone mineral density can begin approximately a year before the last menstrual period. [60]

"If your bones don't hurt, you don't have osteoporosis." Osteoporosis usually occurs without symptoms until a fracture occurs.[61]

"Osteopenia is almost like osteoporosis and definitely requires pills." No. The decision depends on the overall probability of fracture, not just on the T-score being between -1 and -2.5. [62]

"A T-score above -2.5 guarantees safety." No. Bone mineral density is only one component of risk; age, fractures, and other factors are taken into account. [63]

"After menopause, everyone needs to take calcium and vitamin D." The International Menopause Society does not recommend routine combination supplementation for all women without osteoporosis or deficiency conditions simply for the purpose of fracture prevention.[64]

"Hormone therapy doesn't affect bone." It does: it prevents bone loss and reduces the risk of fractures in eligible women. But its role in preventing bone loss in relatively young women differs from the treatment of established high-risk osteoporosis. [65]

“If a fracture has already occurred, it is necessary to first monitor the density for several years.” In contrast, after a typical osteoporotic fracture, timely assessment and treatment are especially important due to the increased risk of recurrent fracture. [66]

Key points from experts

Mary Ann Lumsden is a gynaecologist, Hon Professor of Medical Education and Gynaecology at the University of Glasgow, and the lead author of the European Society of Endocrinology Clinical Practice Guideline on Menopause 2025. Her qualifications and leading role in the development of the document are clearly stated in the publication of the guideline. [67]

The guidelines, prepared by an international group under her leadership, recommend explaining to women that menopausal hormone therapy prevents bone loss and reduces the risk of fracture. At the same time, the document draws a clear distinction: hormone therapy can be used to protect bones in some relatively young women, but for established postmenopausal osteoporosis, specialized bone medications remain the main treatment options. [68]

Nick Panay, BSc, MBBS, FRCOG, MFSRH - Consultant Gynaecologist Imperial College Healthcare NHS Trust, Professor of Practice Imperial College London, Immediate Past-President of the International Menopause Society. His professional biography is endorsed by the International Menopause Society. [69]

The 2025 IMS guidelines, published with Panay as the first author and developed by a large international working group, emphasize that postmenopausal osteoporosis is largely preventable. The guidelines integrate fracture risk assessment, physical activity, adequate nutrition, timely use of hormone therapy in eligible women, and the use of bone-specific medications in high-risk women. [70]

Tobias de Villiers, MBChB, MMed(O&G), FCOG(SA), FRCOG is an obstetrician-gynecologist, a member of the Scientific Advisory Committee of the International Osteoporosis Foundation, chairman of the National Osteoporosis Foundation South Africa, and a former president of the International Menopause Society. His areas of expertise include menopause, hormone therapy, and the effects of estrogens on bone. [71]

In a review of bone health and menopause, de Villiers et al describe a key contemporary management principle: assess not only bone density but the overall fracture probability, stratifying women into low, high, and very high risk and selecting interventions accordingly. [72]

Frequently Asked Questions

At what point after menopause do bones start to weaken faster?

The acceleration can begin even before the last menstrual period. In SWAN, the most rapid decline in density was observed from approximately one year before the last menstrual period to two years after it, after which the rate decreased. [73]

How many years after menopause can osteoporosis appear?

There's no single timeframe. It all depends on the initial peak bone mass, age at menopause, rate of subsequent bone loss, and additional risk factors. Some women will maintain relatively good bone density for decades, while others will experience significant decline much earlier.

Can you feel calcium loss in your bones?

No. A decrease in bone mineral density usually does not cause specific sensations. Pain usually appears after a fracture or its consequences. [74]

Should I have a DXA immediately after my last menstrual period?

Typically, not everyone. Women under 65 are more likely to be tested if they are at increased risk; screening is recommended for women over 65 regardless of symptoms. [75]

If I am 55 years old and healthy, do I need a densitometry test?

Not necessarily immediately. It makes sense to first assess individual risk factors. If these are present, DXA may be indicated before standard age-based screening. [76]

Which is worse - osteopenia or osteoporosis?

Osteoporosis refers to a lower bone mineral density (BMD) as measured by densitometric criteria. However, the actual risk of fracture depends on more than just this category, so a woman with osteopenia and several risk factors sometimes requires more aggressive management than a woman with a similar T-score without them. [77]

Can osteoporosis occur with normal blood calcium levels?

Yes. A normal blood calcium level does not indicate skeletal mineral density and does not rule out osteoporosis. The body tightly regulates blood calcium levels, so osteoporosis diagnosis is not based on a normal serum calcium level.

Will calcium help restore bone density?

If calcium is deficient, correcting the deficiency is necessary. However, calcium supplementation alone is not a complete treatment for the high risk of osteoporotic fractures. [78]

Should I take vitamin D year-round after menopause?

There is no universal requirement for everyone to take supplements. Diet, sun exposure, risk of deficiency, and the clinical situation all play a role. The IMS does not recommend automatically prescribing calcium plus vitamin D to all healthy postmenopausal women solely for fracture prevention. [79]

Does strength training help bones?

Yes. Randomized trials and meta-analyses show a positive effect of resistance training on bone mineral density in some areas of the spine and hip.[80]

Can walking replace strength training?

Walking is beneficial and puts stress on the skeleton, but modern recommendations also include resistance exercises and balance work. [81]

Does hormone therapy protect against osteoporosis?

Yes, systemic estrogen therapy prevents menopausal bone loss and reduces the risk of fractures in eligible women. However, the decision to initiate it depends on age, time since menopause, symptoms, and contraindications. [82]

Should I start hormones just for the sake of bones?

This option may occasionally be considered in women under 60 with a favorable risk profile, but this is not a universal rule. In cases of established high-risk osteoporosis, specialized medications are more often used. [83]

Is it possible to completely cure osteoporosis?

Current guidelines view it as a chronic condition requiring a long-term strategy. Treatment can significantly improve bone health and reduce the risk of fracture, but the concept of "one course of treatment and forgetting about it forever" is inapplicable. [84]

Why can't we just stop denosumab?

Because its effect on bone remodeling rapidly disappears after discontinuation, accelerated loss of mineral density and an increased risk of fractures are possible. Follow-up antiresorptive therapy should be planned before discontinuation. [85]

Should I repeat DXA every year?

Not for everyone. The International Society for Clinical Densitometry recommends individualizing the interval based on age, fracture risk, treatment, and whether the outcome will impact future management. [86]

Main

After menopause, bone tissue does become more vulnerable: reduced estrogen stimulation accelerates remodeling and creates an imbalance in which bone destruction exceeds bone regeneration. The most intense period of bone loss begins around the last menstrual period and then gradually slows, but age-related bone loss continues. [87]

The main danger is that this process is virtually impossible to sense. Therefore, the strategy should be built not around the expectation of pain, but around assessing fracture risk: age, previous fractures, risk factors, FRAX, and, if necessary, DXA. Starting at age 65, bone mineral density screening is recommended for all women; earlier – in those with increased risk. [88]

Physical activity, strength training, fall prevention, and a balanced diet help maintain bone health. Hormone therapy can prevent menopausal bone loss in eligible women, but those at high risk for osteoporotic fractures often require specialized treatment. [89]